Different susceptibility to the parkinson's toxin MPTP in mice lacking the redox master regulator Nrf2 or its target gene heme oxygenase-1

PLoS ONE

Volumn 5, Issue 7, 2010, Pages 1-11

  Innamorato, Nadia G ^a,b   Jazwa, Agnieszka ^a,c   Rojo, Ana I ^a,b   García, Concepción ^a,d   Ferna ́ndez Ruiz, Javier ^a,d   Grochot Przeczek, Anna ^c   Stachurska, Anna ^c   Jozkowicz, Alicja ^c   Dulak, Jozef ^c   Cuadrado, Antonio ^a,b  

^a HOSPITAL UNIVERSITARIO LA PAZ IDIPAZ   (Spain)

^b INSTITUTO DE INVESTIGACIONES BIOMÉDICAS ALBERTO SOLS   (Spain)

^c JAGIELLONIAN UNIVERSITY   (Poland)

^d UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 3,4 DIHYDROXYPHENYLACETIC ACID; DOPAMINE; FERRIC ION; HEME OXYGENASE 1; REGULATOR PROTEIN; TRANSCRIPTION FACTOR NRF2; TYROSINE 3 MONOOXYGENASE; IRON; NEUROTOXIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL COUNT; CONTROLLED STUDY; CORPUS STRIATUM; DENSITOMETRY; DISEASE EXACERBATION; DISEASE PREDISPOSITION; DISEASE SEVERITY; DOPAMINE BRAIN LEVEL; DOPAMINERGIC NERVE CELL; GENE EXPRESSION; GENE TARGETING; GLIOSIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IRON STORAGE; KNOCKOUT MOUSE; MICROGLIA; MOUSE; NISSL STAINING; NONHUMAN; PARKINSONISM; PERL STAINING; PROTEIN EXPRESSION; STAINING; STRIATONIGRAL DEGENERATION; SUBSTANTIA NIGRA; ANIMAL; C57BL MOUSE; CHEMICALLY INDUCED DISORDER; FLUORESCENT ANTIBODY TECHNIQUE; GENETICS; METABOLISM; MOUSE MUTANT; PARKINSON DISEASE; PHYSIOLOGY; POLYMERASE CHAIN REACTION;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOPAMINE; FLUORESCENT ANTIBODY TECHNIQUE; GLIOSIS; HEME OXYGENASE-1; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IRON; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NEUROTOXINS; NF-E2-RELATED FACTOR 2; PARKINSON DISEASE; POLYMERASE CHAIN REACTION;

EID: 77955608828     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0011838     Document Type: Article

References (54)

1. Zeevalk GD, Razmpour R, Bernard LP (2008) Glutathione and Parkinson's disease: is this the elephant in the room? Biomed Pharmacother 62: 236-249.
2. Rojo AI, Montero C, Salazar M, Close RM, Fernandez-Ruiz J, et al. (2006) Persistent penetration of MPTP through the nasal route induces Parkinson's disease in mice. Eur J Neurosci 24: 1874-1884.
3. Langston JW, Ballard P, Tetrud JW, Irwin I (1983) Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219: 979-980.
4. Beal MF (2001) Experimental models of Parkinson's disease. Nat Rev Neurosci 2: 325-334.
5. Bowling AC, Beal MF (1995) Bioenergetic and oxidative stress in neurodegenerative diseases. Life Sci 56: 1151-1171.
6. Cassarino DS, Fall CP, Swerdlow RH, Smith TS, Halvorsen EM, et al. (1997) Elevated reactive oxygen species and antioxidant enzyme activities in animal and cellular models of Parkinson's disease. Biochim Biophys Acta 1362: 77-86.
7. Kushnareva Y, Murphy AN, Andreyev A (2002) Complex I-mediated reactive oxygen species generation: modulation by cytochrome c and NAD(P)+ oxidation-reduction state. Biochem J 368: 545-553.
8. Sherer TB, Betarbet R, Stout AK, Lund S, Baptista M, et al. (2002) An in vitro model of Parkinson's disease: linking mitochondrial impairment to altered alphasynuclein metabolism and oxidative damage. J Neurosci 22: 7006-7015.
9. Castellani R, Smith MA, Richey PL, Perry G (1996) Glycoxidation and oxidative stress in Parkinson disease and diffuse Lewy body disease. Brain Res 737: 195-200.
10. Hirsch EC, Faucheux BA (1998) Iron metabolism and Parkinson's disease. Mov Disord 13 Suppl 1: 39-45.
11. Gao HM, Liu B, Zhang W, Hong JS (2003) Critical role of microglial NADPH oxidase-derived free radicals in the in vitro MPTP model of Parkinson's disease. Faseb J 17: 1954-1956.
12. Hu X, Zhang D, Pang H, Caudle WM, Li Y, et al. (2008) Macrophage antigen complex-1 mediates reactive microgliosis and progressive dopaminergic neurodegeneration in the MPTP model of Parkinson's disease. J Immunol 181: 7194-7204.
13. Harman D (1956) Aging: a theory based on free radical and radiation chemistry. J Gerontol 11: 298-300.
14. Barja G (2002) Rate of generation of oxidative stress-related damage and animal longevity. Free Radic Biol Med 33: 1167-1172.
15. Cuadrado A, Moreno-Murciano P, Pedraza-Chaverri J (2009) The transcription factor Nrf2 as a new therapeutic target in Parkinson's disease. Expert Opin Ther Targets 13: 319-329.
16. Olivares D, Huang X, Branden L, Greig NH, Rogers JT (2009) Physiological and Pathological Role of Alpha-synuclein in Parkinson's Disease Through Iron Mediated Oxidative Stress; The Role of a Putative Iron-responsive Element. Int J Mol Sci 10: 1226-1260.
17. Innamorato NG, Rojo AI, Garcia-Yague AJ, Yamamoto M, de Ceballos ML, et al. (2008) The transcription factor Nrf2 is a therapeutic target against brain inflammation. J Immunol 181: 680-689.
18. Lee JM, Calkins MJ, Chan K, Kan YW, Johnson JA (2003) Identification of the NF-E2-related factor-2-dependent genes conferring protection against oxidative stress in primary cortical astrocytes using oligonucleotide microarray analysis. J Biol Chem 278: 12029-12038.
19. Shih AY, Johnson DA, Wong G, Kraft AD, Jiang L, et al. (2003) Coordinate regulation of glutathione biosynthesis and release by Nrf2-expressing glia potently protects neurons from oxidative stress. J Neurosci 23: 3394-3406.
20. Lo SC, Li X, Henzl MT, Beamer LJ, Hannink M (2006) Structure of the Keap1:Nrf2 interface provides mechanistic insight into Nrf2 signaling. Embo J 25: 3605-3617.
21. Katsuoka F, Motohashi H, Ishii T, Aburatani H, Engel JD, et al. (2005) Genetic evidence that small maf proteins are essential for the activation of antioxidant response element-dependent genes. Mol Cell Biol 25: 8044-8051.
22. Dinkova-Kostova AT, Holtzclaw WD, Cole RN, Itoh K, Wakabayashi N, et al. (2002) Direct evidence that sulfhydryl groups of Keap1 are the sensors regulating induction of phase 2 enzymes that protect against carcinogens and oxidants. Proc Natl Acad Sci U S A 99: 11908-11913.
23. Burton NC, Kensler TW, Guilarte TR (2006) In vivo modulation of the Parkinsonian phenotype by Nrf2. Neurotoxicology 27: 1094-1100.
24. Chen PC, Vargas MR, Pani AK, Smeyne RJ, Johnson DA, et al. (2009) Nrf2- mediated neuroprotection in the MPTP mouse model of Parkinson's disease: Critical role for the astrocyte. Proc Natl Acad Sci U S A 106: 2933-2938.
25. Rojo AI, Innamorato NG, Martin-Moreno AM, De Ceballos ML, Yamamoto M, et al. (2009) Nrf2 regulates microglial dynamics and neuroinflammation in experimental Parkinson's disease. Glia 58: 588-598.
26. Boczkowski J, Poderoso JJ, Motterlini R (2006) CO-metal interaction: Vital signaling from a lethal gas. Trends Biochem Sci 31: 614-621.
27. Bilban M, Haschemi A, Wegiel B, Chin BY, Wagner O, et al. (2008) Heme oxygenase and carbon monoxide initiate homeostatic signaling. J Mol Med 86: 267-279.
28. Piantadosi CA (2008) Carbon monoxide, reactive oxygen signaling, and oxidative stress. Free Radic Biol Med 45: 562-569.
29. Cuadrado A, Rojo AI (2008) Heme oxygenase-1 as a therapeutic target in neurodegenerative diseases and brain infections. Curr Pharm Des 14: 429-442.
30. Li MH, Cha YN, Surh YJ (2006) Peroxynitrite induces HO-1 expression via PI3K/Akt-dependent activation of NF-E2-related factor 2 in PC12 cells. Free Radic Biol Med 41: 1079-1091.
31. Samoylenko A, Dimova EY, Horbach T, Teplyuk N, Immenschuh S, et al. (2008) Opposite expression of the antioxidant heme oxygenase-1 in primary cells and tumor cells: regulation by interaction of USF-2 and Fra-1. Antioxid Redox Signal 10: 1163-1174.
32. Huang E, Ong WY, Go ML, Garey LJ (2005) Heme oxygenase-1 activity after excitotoxic injury: immunohistochemical localization of bilirubin in neurons and astrocytes and eleterious effects of heme oxygenase inhibition on neuronal survival after kainate treatment. J Neurosci Res 80: 268-278.
33. Hung SY, Liou HC, Kang KH, Wu RM, Wen CC, et al. (2008) Overexpression of heme oxygenase-1 protects dopaminergic neurons against 1-methyl-4-phenylpyridinium-induced neurotoxicity. Mol Pharmacol 74: 1564-1575.
34. Glinka Y, Tipton KF, Youdim MB (1996) Nature of inhibition of mitochondrial respiratory complex I by 6-Hydroxydopamine. J Neurochem 66: 2004-2010.
35. Ben-Shachar D, Eshel G, Finberg JP, Youdim MB (1991) The iron chelatordesferrioxamine (Desferal) retards 6-hydroxydopamine-induced degeneration of nigrostriatal dopamine neurons. J Neurochem 56: 1441-1444.
36. Grunblatt E, Mandel S, Berkuzki T, Youdim MB (1999) Apomorphine protects against MPTP-induced neurotoxicity in mice. Mov Disord 14: 612-618.
37. Schipper HM, Liberman A, Stopa EG (1998) Neural heme oxygenase-1expression in idiopathic Parkinson's disease. Exp Neurol 150: 60-68.
38. Morris CM, Edwardson JA (1994) Iron histochemistry of the substantia nigra in Parkinson's disease. Neurodegeneration 3: 277-282.
39. Itoh K, Chiba T, Takahashi S, Ishii T, Igarashi K, et al. (1997) An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. Biochem Biophys Res Commun 236: 313-322.
40. Tsuchihashi S, Livhits M, Zhai Y, Busuttil RW, Araujo JA, et al. (2006) Basal rather than induced heme oxygenase-1 levels are crucial in the antioxidant cytoprotection. J Immunol 177: 4749-4757.
41. West MJ (1993) New stereological methods for counting neurons. Neurobiol Aging 14: 275-285.
42. Schipper HM, Song W, Zukor H, Hascalovici JR, Zeligman D (2009) Heme oxygenase-1 and neurodegeneration: expanding frontiers of engagement. J Neurochem 110: 469-485.
43. Gille G, Hung ST, Reichmann H, Rausch WD (2004) Oxidative stress to dopaminergic neurons as models of Parkinson's disease. Ann N Y Acad Sci 1018: 533-540.
44. Chinta SJ, Kumar MJ, Hsu M, Rajagopalan S, Kaur D, et al. (2007) Inducible alterations of glutathione levels in adult dopaminergic midbrain neurons result in nigrostriatal degeneration. J Neurosci 27: 13997-14006.
45. Sofic E, Paulus W, Jellinger K, Riederer P, Youdim MB (1991) Selective increase of iron in substantia nigra zona compacta of parkinsonian brains. J Neurochem 56: 978-982.
46. Berg D, Gerlach M, Youdim MB, Double KL, Zecca L, et al. (2001) Brain ironpathways and their relevance to Parkinson's disease. J Neurochem 79: 225-236.
47. Mochizuki H, Imai H, Endo K, Yokomizo K, Murata Y, et al. (1994) Iron accumulation in the substantia nigra of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced hemiparkinsonian monkeys. Neurosci Lett 168: 251-253.
48. Mandel S, Grunblatt E, Maor G, Youdim MB (2002) Early and late gene changes in MPTP mice model of Parkinson's disease employing cDNA microarray. Neurochem Res 27: 1231-1243.
49. Grunblatt E, Mandel S, Maor G, Youdim MB (2001) Gene expression analysis in N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mice model of Parkinson's disease using cDNA microarray: effect of R-apomorphine. J Neurochem 78: 1-12.
50. Youdim MB, Ben-Shachar D, Riederer P (1993) The possible role of iron in the etiopathology of Parkinson's disease. Mov Disord 8: 1-12.
51. Lin Q, Weis S, Yang G, Weng YH, Helston R, et al. (2007) Heme oxygenase-1 protein localizes to the nucleus and activates transcription factors important in oxidative stress. J Biol Chem 282: 20621-20633.
52. Turkseven S, Drummond G, Rezzani R, Rodella L, Quan S, et al. (2007) Impact of silencing HO-2 on EC-SOD and the mitochondrial signaling pathway. J Cell Biochem 100: 815-823.
53. Snyder AM, Connor JR (2009) Iron, the substantia nigra and related neurological disorders. Biochim Biophys Acta 1790: 606-614.
54. Salazar J, Mena N, Hunot S, Prigent A, Alvarez-Fischer D, et al. (2008) Divalentmetal transporter 1 (DMT1) contributes to neurodegeneration in animal models of Parkinson's disease. Proc Natl Acad Sci U S A 105: 18578-18583.